Patients with end-stage renal disease require permanent vascular access to enable safe and effective hemodialysis. An arteriovenous fistula (AVF), where a vein is mobilized and connected to an artery in the arm, is considered the gold standard and first choice for vascular access. After fistula creation, the vein is subjected to high pressure and flow, and undergoes remodeling. This includes the possibility of significant dilatation and intimal hyperplasia. Normal AVF flow required for effective dialysis is around 0.6 liters/min or 0.4-0.8 liters/min. However, in at least 20% of patients, excessive remodeling and dilatation of the fistula result in a high flow AVF with \>2 liters/min. High flow fistulas significantly increase the risk for the development of high output cardiac failure, skin breakdown, bleeding, hand ischemia, and other systemic complications. In cases of high flow AVF, venous reconstruction procedures, banding and/or plication, are often required to limit venous diameter and flow. The longevity of this procedure is limited as the reconstructed segment remodels and re-dilates due to ongoing arterial pressure. Banding and plication are both procedures that are designed to increase resistance to flow. Banding is performed by wrapping a segment of polytetrafluoroethylene (PTFE) around the outflow tract of the fistula, or by placing a suture around the fistula near the arterial anastomotic area to create a narrowing. Fistula plication involves narrowing of a short segment of the proximal venous outflow tract, usually accomplished by suturing or stapling the fistula for 2-6 cm. One of the notable systemic effects of a hemodialysis AVF is an acute decrease in systemic vascular resistance with a simultaneous increase in venous return to the heart, and thus an increase of the cardiac output. Cardiac failure occurs more frequently in patients with an access flow QA\>2 l/min and CPR≥20%. Another adverse systemic effect of AV fistulas is pulmonary hypertension. The increased flow volume to the heart from an AV fistula yields an increase in pulmonary pressures. This can limit pulmonary vasodilation and result in pulmonary hypertension.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
21
The surgeon will use the medical device FRAME to perform the plication procedure. The device will be selected and implanted according to the product IFU.
Groupe Hospitalier Paris Saint-Joseph
Paris, France
Fistula flow Evaluation M6
The primary outcome of the research is to evaluate the fistula flow by Doppler Us and the fistula primary patency rate over time.
Time frame: Month 6
Fistula flow Evaluation M12
The primary outcome of the research is to evaluate the fistula flow by Doppler Us and the fistula primary patency rate over time
Time frame: Month12
Occurence of safety events
This outcome corresponds to the number of safety events such as death, infection, ongoing steal, recurrent aneurysm, new cephalic arch stenosis, fistula thrombosis.
Time frame: at 6 and 12 months
Evaluation of the functional fistula patency
This ouctome corresponds to functional fistula patency.
Time frame: at 6 and 12 months
Cardiac parameters
CPR = QA/CO ratio
Time frame: at 12 months
Secondary patency
This outcome corresponds to the evaluation of thrombosis and AVF discontinuation at 6 and 12 months.
Time frame: at 6 and 12 months
Patient's Quality of Life SF-36
The SF-36 questionnaire consists of 36 items, which are used to calculate eight subscales: physical functioning (PF), role physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE), and mental health (MH). The first four scores can be summed to create the physical composite score (PCS), while the last four can be summed to create the mental composite score (MCS). Scores for the SF-36 scales range between 0 and 100, with higher scores indicating a better HRQOL.
Time frame: at 6 and 12 months
Reintervention
This outcome is to evaluate the number of patients who had a surgical or endovascular reintervention at 6 and 12 months.
Time frame: at 6 and 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.